Retatrutide · research summary

Beyond Fat Loss: Addressing the Sarcopenia Challenge of Incretin-Based Therapies.

Diabetes & metabolism journal · 2026. Summary drawn from the study's full text. Each statement is followed by the exact sentence it comes from. This is a research summary, not medical advice.

Study type

Narrative review of clinical trials and meta-analyses regarding body composition changes during incretin-based therapy
“This review first clarifies how muscle change should be evaluated and interpreted by integrating body-composition measures with muscle strength, muscle quality, and physical performance.”

Subjects

Adults with type 2 diabetes mellitus and obesity
“Incretin-based therapies have transformed the treatment of type 2 diabetes mellitus and obesity by producing a weight-loss magnitude that was previously achievable only through intensive caloric restriction or bariatric surgery.”

Duration

Approximately 24 to 72 weeks for observed body-composition changes
“Third, the observed changes occur over approximately 24 to 72 weeks, far more rapidly than the gradual muscle loss associated with physiological aging.”

Reported findings

Incretin-based therapies reduce fat mass more than lean mass, with lean mass loss accounting for approximately 25-40% of total weight loss
“Lean mass loss accounted for approximately one-quarter of total weight loss, while relative lean mass, expressed as the proportion of lean mass within the total body weight, was largely preserved.”
Available evidence does not show consistent deterioration in muscle strength or physical function, though long-term data are limited
“Overall, available studies have not demonstrated consistent deterioration in functional outcomes and frequently report improvement in patient-reported physical function or exercise capacity.”
Incretin-based therapy may improve muscle quality through reduced myosteatosis despite reductions in muscle volume
“Collectively, these findings suggest that incretin-based therapy may improve muscle quality, particularly through reductions in myosteatosis, despite concomitant reductions in muscle quantity or lean mass [36,40].”

Limitations stated by the authors

Long-term data are limited, especially in people with reduced muscle reserve, and most trials were not designed to diagnose sarcopenia
“Available evidence does not show obvious functional harm; however, long-term data remain limited, especially in people with reduced muscle reserve.”

Source: PubMed 42722378 · DOI 10.4093/dmj.2026.0702 · all study summaries

Study type

Narrative review of clinical trials and meta-analyses regarding body composition changes during incretin-based therapy

“This review first clarifies how muscle change should be evaluated and interpreted by integrating body-composition measures with muscle strength, muscle quality, and physical performance.”

Reported findings

Incretin-based therapies reduce fat mass more than lean mass, with lean mass loss accounting for approximately 25-40% of total weight loss

“Lean mass loss accounted for approximately one-quarter of total weight loss, while relative lean mass, expressed as the proportion of lean mass within the total body weight, was largely preserved.”

Available evidence does not show consistent deterioration in muscle strength or physical function, though long-term data are limited

“Overall, available studies have not demonstrated consistent deterioration in functional outcomes and frequently report improvement in patient-reported physical function or exercise capacity.”

Incretin-based therapy may improve muscle quality through reduced myosteatosis despite reductions in muscle volume

“Collectively, these findings suggest that incretin-based therapy may improve muscle quality, particularly through reductions in myosteatosis, despite concomitant reductions in muscle quantity or lean mass [36,40].”